ALMS Alumis Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
18:23
Sep 01
Sep 01
ALMS lacks blockbuster psoriasis drug
Author is bearish on ALMS by rejecting the blockbuster psoriasis-drug thesis and calling the Otezla comparator weak, but does not disclose a short position or explicit short call.
MED
16:55
Sep 01
Sep 01
Short ALMS; Sotyktu failure shows high bar.
Author argues ALMS should not spend to launch against JNJ/TAK because Sotyktu's weak commercial uptake shows the market bar is high, but does not disclose a short position or explicit short call.
MED
14:07
Sep 01
Sep 01
ALMS toward zero on cash burn, competition.
Short ALMS because SLE failure leaves a cash-burning biomarker-selected P3 program, with $142M quarterly burn against $500M cash and oral psoriasis competition from Takeda and Icotyde structurally limiting its market.
HIGH
12:56
Aug 17
Aug 17
Reports heaviest selling across specialist funds
"Reports net conviction laggards with heaviest genuine selling across specialist funds in Q2 2026, no directional view."
MED
About ALMS Analyst Coverage
Buzzberg tracks ALMS (Alumis Inc.) across 2 sources. 0 bullish vs 1 bearish calls from 2 analysts. Sentiment: mixed to bearish. 4 total trade ideas tracked. Past 7 days: 1 bearish, 2 watch. Latest voices: A May MD, seedy19tron.